CN116850176A - Application of ginkgetin in preparation of medicine for treating non-small cell lung cancer - Google Patents
Application of ginkgetin in preparation of medicine for treating non-small cell lung cancer Download PDFInfo
- Publication number
- CN116850176A CN116850176A CN202311007374.1A CN202311007374A CN116850176A CN 116850176 A CN116850176 A CN 116850176A CN 202311007374 A CN202311007374 A CN 202311007374A CN 116850176 A CN116850176 A CN 116850176A
- Authority
- CN
- China
- Prior art keywords
- lung cancer
- ginkgetin
- small cell
- cell lung
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002154 non-small cell lung carcinoma Diseases 0.000 title claims abstract description 64
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 title claims abstract description 63
- SQGLUEWZRKIEGS-UHFFFAOYSA-N Ginkgetin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OC)C(C=3C(=CC=C(C=3)C=3OC4=CC(O)=CC(O)=C4C(=O)C=3)O)=C2O1 SQGLUEWZRKIEGS-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 229930045534 Me ester-Cyclohexaneundecanoic acid Natural products 0.000 title claims abstract description 59
- AIFCFBUSLAEIBR-UHFFFAOYSA-N ginkgetin Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C(C=1)=CC=C(OC)C=1C1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 AIFCFBUSLAEIBR-UHFFFAOYSA-N 0.000 title claims abstract description 59
- 239000003814 drug Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 230000035755 proliferation Effects 0.000 claims abstract description 17
- 230000005012 migration Effects 0.000 claims abstract description 8
- 238000013508 migration Methods 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 6
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 claims description 20
- 108010017324 STAT3 Transcription Factor Proteins 0.000 claims description 20
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 claims description 20
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 18
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 4
- 230000009702 cancer cell proliferation Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000003560 cancer drug Substances 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 65
- 238000011160 research Methods 0.000 description 14
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 8
- 201000005202 lung cancer Diseases 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 108010060273 Cyclin A2 Proteins 0.000 description 4
- 108010058546 Cyclin D1 Proteins 0.000 description 4
- 102100025191 Cyclin-A2 Human genes 0.000 description 4
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 4
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000009822 protein phosphorylation Effects 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 230000007730 Akt signaling Effects 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 229940124783 FAK inhibitor Drugs 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- UFJORDZSBNSRQT-UHFFFAOYSA-N 3-(4-oxo-2-phenylchromen-3-yl)-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(C=2C(C3=CC=CC=C3OC=2C=2C=CC=CC=2)=O)=C1C1=CC=CC=C1 UFJORDZSBNSRQT-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000218628 Ginkgo Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Steroid Compounds (AREA)
Abstract
The invention discloses application of ginkgetin in preparation of a medicine for treating non-small cell lung cancer, and belongs to the technical field of medicines. The invention discovers that the ginkgetin can obviously inhibit proliferation and migration of non-small cell lung cancer cells, and has application prospect in developing non-small cell lung cancer drugs.
Description
Technical Field
The invention belongs to the technical field of medicines, and particularly relates to application of ginkgetin in preparation of a medicine for treating non-small cell lung cancer.
Background
In malignant tumors, the incidence and mortality of lung cancer are the first. Non-small cell lung cancer (Non-small cell lung cancer, NSCLC) is the most common histological type of lung cancer, accounting for approximately 85% of the total lung cancer. The root cause of such high mortality of lung cancer is that lung cancer has no clinical symptoms in early stages, and most lung cancer patients have metastasized when diagnosed in middle and late stages.
Traditional lung cancer treatment methods mainly comprise surgical excision, radiotherapy and chemotherapy. In recent years, with rapid development of genomics, targeted therapy and immunotherapy have become important means for anti-tumor. However, it is disappointing that resistance occurs in almost all targeted drugs, which greatly affects the survival rate of the targeted therapy patients.
Ginkgo biloba extract (Ginkgetin) is a biflavone isolated from folium Ginkgo, and has neuroprotective, antitumor, antiinflammatory and antifungal effects. Ginkgetin has been found to inhibit the growth of a variety of tumors including prostate, breast, colon and liver cancer. In addition, ginkgetin has been reported to enhance the therapeutic effect of cisplatin by inducing iron death in non-small cell lung cancer cells; however, the anti-lung cancer effect of Ginkgetin and its molecular mechanism are not yet known.
Disclosure of Invention
Against the background of the above research, the inventor considers that ginkgetin is expected to be developed into an anti-tumor drug to be applied, and the invention aims to provide the application of ginkgetin in preparing a drug for treating non-small cell lung cancer. The effect of ginkgetin on inhibiting proliferation and migration of non-small cell lung cancer cells is proved by in vitro cell experiments; specifically, the ginkgetin can inhibit proliferation of non-small cell lung cancer cells by inhibiting EGF-mediated FAK/STAT3/AKT phosphorylation. In addition, ginkgetin inhibits the expression of Ki67, cyclin a2 and cyclin d1 proteins in non-small cell lung cancer cells.
The invention provides application of ginkgetin in preparation of a medicine for treating non-small cell lung cancer, wherein the ginkgetin in the medicine treats the non-small cell lung cancer through a FAK/STAT3/AKT channel.
Preferably, the medicament is for inhibiting proliferation and migration of non-small cell lung cancer cells.
Preferably, the drug inhibits non-small cell lung cancer cell proliferation by inhibiting EGF-mediated FAK, STAT3 and AKT activity.
Preferably, the medicament consists of a therapeutically effective amount of ginkgetin and pharmaceutically acceptable auxiliary materials and/or excipients.
Preferably, the ginkgetin in the medicine is used as an active ingredient and accounts for 1-99% of the total mass.
Preferably, the medicament is in the form of a tablet, capsule, powder, syrup, solution, suspension or aerosol
The invention has the beneficial effects that the ginkgetin is found to obviously inhibit proliferation and migration of non-small cell lung cancer cells, and the ginkgetin is suggested to be developed as a non-small cell lung cancer drug. The invention mainly focuses on the research of anti-non-small cell lung cancer drugs for reducing FAK, STAT3 and AKT phosphorylation expression in non-small cell lung cancer cells.
Drawings
FIG. 1 is a bar graph showing the results of a Ginkgetin inhibition of non-small cell lung cancer cell proliferation assay.
FIG. 2 is a fluorescent chart showing the results of the inhibition of Ki67 protein expression in non-small cell lung cancer cells by Ginkgetin.
FIG. 3 is a graph showing the results of an experiment for inhibiting the colony formation of non-small cell lung cancer cells by Ginkgetin.
FIG. 4 is a graph showing the results of an experiment for the down-regulation of FAK/STAT3/AKT protein phosphorylation in non-small cell lung cancer cells by Ginkgetin.
FIG. 5 is a graph showing the results of an experiment for blocking EGF-induced FAK/STAT3/AKT pathway phosphorylation expression in non-small cell lung cancer by Ginkgetin.
FIG. 6 is a bar graph showing the results of proliferation experiments of Ginkgetin in inhibiting non-small cell lung cancer cells through EGF-mediated FAK/STAT3/AKT signaling pathway.
FIG. 7 is a bar graph showing the results of a Ginkgetin inhibition test for non-small cell lung cancer cell migration.
FIG. 8 is a graph showing the results of experiments on the inhibition of cyclin A2 and cyclin D1 expression in non-small cell lung cancer cells by Ginkgetin.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be clearly and completely described in the following examples. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The term "and/or" as used herein includes any and all combinations of one or more of the associated listed items.
Example 1 cell viability assay
The invention adopts non-small cell lung cancer cell strains A549 and H1299 as research objects to research the influence of Ginkgetin on the proliferation of the non-small cell lung cancer cells. Cells were treated with varying concentrations (0,1,2.5,5, 10, 20. Mu.M) of Ginkgetin, and after 24 hours incubation, CCK8 (purchased from GlpBio) was added for 2 hours to observe the inhibition of proliferation of non-small cell lung cancer cells by Ginkgetin. The results of FIG. 1 show that Ginkgetin has an inhibitory effect on proliferation of non-small cell lung cancer cells and is concentration-dependent. In order to further detect the influence of the Ginkgetin effect on the cell viability at different times, the cells are treated for 24h, 48h and 72h respectively, and the Ginkgetin is found to obviously inhibit the proliferation of non-small cell lung cancer cells in a dose-dependent and time-dependent manner after detection, and the inhibition effect is more obvious as the inhibition time is longer (shown in figure 1).
Example 2 cell immunofluorescence assay
The invention adopts non-small cell lung cancer cell strains A549 and H1299 as research objects to research the influence of Ginkgetin on Ki67 protein expression in non-small cell lung cancer cells. Cells were seeded in 12-well plates and, after adherence, treated with 2.5. Mu.M and 10. Mu.M Ginkgetin for 48h. Washing 3 times with precooled PBS, and adding 4% paraformaldehyde for fixing for 15min. After fixation, the membrane was broken by washing 3 times with pre-chilled PBS and adding 0.25% Triton-100 (0.25% Triton X-100in PBS) for 10min. Subsequently, blocking was performed with 1% BSA in PBST (0.1% Tween-20). After blocking, 200ul of ki67 antibody (cat.no.27309-1-AP; proteintech, wuhan, china) was added to each well and incubated overnight in a wet box at 4 ℃. After washing with PBS, goat anti-mouse fluorescent secondary antibody (cat.no. ab 150080) was added for incubation for 1h, and then cell nuclei were stained with DAPI, and fluorescent signal detection was performed under an inverted fluorescent microscope, and it was observed from FIG. 2 that Ginkgetin inhibited Ki67 protein expression in non-small cell lung cancer cells.
EXAMPLE 3 cloning colony formation experiments
The invention adopts non-small cell lung cancer cell strains A549 and H1299 as research objects to research the influence of Ginkgetin on the formation of non-small cell lung cancer cell clone colonies. Cells were seeded at a density of 200 cells/well in 6-well plates and after adherence, treated with 2.5. Mu.M and 10. Mu.M Ginkgetin. After two weeks, old medium was aspirated, washed once with PBS and cells were fixed with 4% paraformaldehyde for 20min. After fixing, crystal violet is added for dyeing for 1min, and then excessive crystal violet is washed away by slow running water, dried and photographed. FIG. 3 shows that Ginkgetin inhibits the formation of colonies of non-small cell lung cancer cell clones.
Example 4Ginkgetin down-regulates expression of FAK/STAT3/AKT protein phosphorylation in non-small cell lung cancer cells
According to the invention, non-small cell lung cancer cell strains A549 and H1299 are taken as research objects, and the influence of Ginkgetin on the phosphorylation expression of FAK/STAT3/AKT protein in non-small cell lung cancer cells is researched. Cells were treated with varying concentrations (0,1,2.5,5, 10, 20. Mu.M) of Ginkgetin for 24h, and changes in the phosphorylated expression of FAK, STAT3 and AKT proteins in the cells were detected by Western Blot, and it was observed from FIG. 4 that the greater the Ginkgetin concentration, the greater the inhibitory effect on the phosphorylated expression of FAK/STAT3/AKT proteins in non-small cell lung cancer cells.
Example 5Ginkgetin blocks EGF-induced FAK/STAT3/AKT pathway phosphorylation expression in non-Small cell lung cancer cells
According to the invention, non-small cell lung cancer cell strains A549 and H1299 are taken as research objects, and whether Ginkgetin regulates proliferation of non-small cell lung cancer cells by inhibiting FAK/STAT3/AKT signal channels is researched. After stimulating cells with 10. Mu.M Ginkgetin, the expression of FAK, STAT3 and AKT phosphorylation in non-small cell lung cancer cells was activated with 20ng/mL EGF, and Western Blot was used to detect changes in the expression of FAK, STAT3 and AKT protein phosphorylation in cells, and it was observed from FIG. 5 that Ginkgetin inhibited EGF-induced levels of FAK, STAT3 and AKT phosphorylation.
Example 6Ginkgetin inhibits proliferation of non-small cell lung cancer cells through EGF-mediated FAK/STAT3/AKT signaling pathway
According to the invention, non-small cell lung cancer cell strains A549 and H1299 are taken as research objects, and whether Ginkgetin inhibits proliferation of non-small cell lung cancer cells through EGF-mediated FAK/STAT3/AKT signal pathway is researched. In the presence or absence of EGF, the proliferation of EGF-induced non-small cell lung cancer cells was significantly inhibited by Ginkgetin as shown in FIG. 6, which was examined by adding CCK8 to the cells after treating them with 10. Mu.M Ginkgetin for 72 hours. Similarly, in the presence or absence of EGF, after treating the cells with 10. Mu.M of FAK inhibitor PF-562271 for 72 hours, the cells were examined by adding CCK8 for 2 hours, and it was observed from FIG. 6 that FAK inhibitor PF-562271 also significantly inhibited EGF-induced proliferation of non-small cell lung cancer cells.
Example 7 cell scratch assay
The invention adopts non-small cell lung cancer cell strains A549 and H1299 as research objects to research the influence of Ginkgetin on the proliferation or migration of non-small cell lung cancer cells. Cells were seeded in 6-well plates, attached overnight, and then a 200 μl gun head was used to scratch the cells into a wound and imaged under a microscope, which was recorded as 0h. Cells were then treated with 1. Mu.M and 5. Mu.M Ginkgetin, and the cells were imaged under a microscope at 24h and 48h, respectively, and the degree of migration of the cells was measured, as shown in FIG. 7, in which Ginkgetin inhibited migration of non-small cell lung cancer cells.
Example 8Ginkgetin inhibits the expression of CyclinA2 and CyclinD1 proteins in non-Small cell lung cancer cells
According to the invention, non-small cell lung cancer cell strains A549 and H1299 are used as research objects, and the influence of Ginkgetin on the expression of cyclin A2 and cyclin D1 in non-small cell lung cancer cells is researched. After cells were stimulated for 24h with varying concentrations (0,1,2.5,5, 10, 20. Mu.M) of Ginkgetin, the changes in the expression of the cyclin A2 and cyclin D1 proteins in the cells were detected by Western Blot, and it was observed from FIG. 8 that Ginkgetin significantly down-regulated the cyclin A2 and cyclin D1 protein expression.
The embodiments described above represent only a few preferred embodiments of the present invention, which are described in more detail and are not intended to limit the present invention. It should be noted that various changes and modifications can be made to the present invention by those skilled in the art, and any modifications, equivalent substitutions, improvements, etc. which are within the spirit and principle of the present invention are included in the scope of the present invention.
Claims (6)
1. The application of ginkgetin in preparing a medicine for treating non-small cell lung cancer is characterized in that the ginkgetin in the medicine treats the non-small cell lung cancer through a FAK/STAT3/AKT channel.
2. The use according to claim 1, wherein the medicament is for inhibiting proliferation and migration of non-small cell lung cancer cells.
3. The use according to claim 2, wherein the drug inhibits non-small cell lung cancer cell proliferation by inhibiting EGF-mediated FAK, STAT3 and AKT activity.
4. The use according to claim 1, wherein the medicament consists of a therapeutically effective amount of ginkgetin and pharmaceutically acceptable excipients and/or excipients.
5. The use according to claim 4, wherein the ginkgetin in the medicament is 1-99% of the total mass as an active ingredient.
6. The use according to claim 4, wherein the pharmaceutical is in the form of a tablet, capsule, powder, syrup, solution, suspension or aerosol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311007374.1A CN116850176A (en) | 2023-08-10 | 2023-08-10 | Application of ginkgetin in preparation of medicine for treating non-small cell lung cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311007374.1A CN116850176A (en) | 2023-08-10 | 2023-08-10 | Application of ginkgetin in preparation of medicine for treating non-small cell lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116850176A true CN116850176A (en) | 2023-10-10 |
Family
ID=88232387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311007374.1A Pending CN116850176A (en) | 2023-08-10 | 2023-08-10 | Application of ginkgetin in preparation of medicine for treating non-small cell lung cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116850176A (en) |
-
2023
- 2023-08-10 CN CN202311007374.1A patent/CN116850176A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tsang et al. | Berberine suppresses tumorigenicity and growth of nasopharyngeal carcinoma cells by inhibiting STAT3 activation induced by tumor associated fibroblasts | |
| Chen et al. | Astragalin-induced cell death is caspase-dependent and enhances the susceptibility of lung cancer cells to tumor necrosis factor by inhibiting the NF-κB pathway | |
| Yang et al. | Oridonin suppresses human gastric cancer growth in vitro and in vivo via inhibition of VEGF, integrin β3, and PCNA | |
| Gan et al. | Natural product pectolinarigenin exhibits potent anti-metastatic activity in colorectal carcinoma cells in vitro and in vivo | |
| Zhang et al. | Andrographolide, a diterpene lactone from the Traditional Chinese Medicine Andrographis paniculate, induces senescence in human lung adenocarcinoma via p53/p21 and Skp2/p27 | |
| Cai et al. | β-Elemene triggers ROS-dependent apoptosis in glioblastoma cells through suppressing STAT3 signaling pathway | |
| Zhang et al. | Radix tetrastigma extracts enhance the chemosensitivity in triple-negative breast cancer via inhibiting PI3K/Akt/mTOR-mediated autophagy | |
| CN106265760B (en) | Clostridium ghonii tames application of the strain in radiotherapeutic sensitizer is prepared | |
| Wang et al. | Therapeutic mechanism and effect of camptothecin on dextran sodium sulfate-induced ulcerative colitis in mice | |
| CN109529041B (en) | Application of spleen tyrosine kinase as target for treating intrahepatic bile duct cell cancer | |
| Tu et al. | Icaritin ameliorates extracellular microparticles‐induced inflammatory pre‐metastatic niche via modulating the cGAS‐STING signaling | |
| CN116850176A (en) | Application of ginkgetin in preparation of medicine for treating non-small cell lung cancer | |
| CN115337313A (en) | Application of cucurbitacin E in preparation of medicine for treating brain glioma through FAK/AKT/GSK3 beta pathway | |
| Alshaymaa et al. | Regression of murine Ehrlich ascites carcinoma using tumor-targeting Salmonella VNP20009-comparison with the effect of the anticancer drug doxorubicin | |
| CN112891351B (en) | Application of naphthalimide-polyamine derivative and mitoxantrone in preparation of antitumor drugs | |
| AU2020255063B2 (en) | Combined use of A-nor-5α androstane compound drug and anticancer drug | |
| CN114558141A (en) | Promoter for reducing malignant phenotype of pancreatic cancer cells, pharmaceutical composition and application thereof | |
| WO2020215843A1 (en) | Combined drug of gossypol acetic acid and chemotherapeutic drug | |
| Li et al. | Chidamide suppresses the growth of cholangiocarcinoma by inhibiting HDAC3 and promoting FOXO1 acetylation | |
| Yao-Dong et al. | The anti-neoplastic activities of aloperine in HeLa cervical cancer cells are associated with inhibition of the IL-6-JAK1-STAT3 feedback loop | |
| Li et al. | N-((1-(4-Fluorophenyl)-1H-1, 2, 3-triazol-4-yl) methyl)-2-methylene-3-oxo-olean-12-en-28-amide induces apoptosis in human breast cancer cells by stimulating oxidative stress and inhibiting the notch-akt signaling pathway | |
| CN116832041A (en) | Application of evodiamine in preparation of medicines for treating non-small cell lung cancer | |
| Li et al. | Investigation of the inhibitory effect of platycodin D in human transitional cell carcinoma cell line 5637 | |
| CN108379583A (en) | A kind of target of tumor metastasis medicine treatment and its application | |
| CN111494397B (en) | Application of ophiopogonin compounds in preparing medicines for preventing and treating tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |